From data to decisions: How pharma can move faster without sacrificing trust

Pharma's speed advantage depends on trust. Is your data foundation strong enough?

By Pankit Bhalodia, Partner at West Monroe Life Sciences • July 14, 2025

Jazz names new CEO; Ultragenyx, Mereo shares slide on trial update

Current operations chief Renee Gala will succeed Bruce Cozadd at Jazz. Meanwhile, Nuclidium raised about $99 million to develop radiopharmaceuticals that involve copper isotopes.

By BioPharma Dive staff • July 11, 2025

Explore the Trendline➔

Alzheimer's disease

Many companies hope to follow in the footsteps of Biogen, Eisai and Eli Lilly by developing new therapies for the debilitating disease, which affects tens of millions of people and costs healthcare systems hundreds of billions of dollars each year.

By BioPharma Dive staff

AbbVie to pay $700M for trispecific drug from Ichnos Glenmark

The deal hands AbbVie a drug that’s shown early promise in multiple myeloma and may be useful treating other cancers and autoimmune conditions, too. 

By Kristin Jensen • July 10, 2025

Gilead signs lenacapavir access deal; Arvinas CEO to step down

The drugmaker will provide, at no profit, doses to treat up to 2 million people in resource-limited countries. Meanwhile, Arvinas' John Houston is retiring from his role leading the biotech.

By BioPharma Dive staff • July 9, 2025

Trump says pharmaceutical, copper tariffs coming ‘very soon’

While Trump indicated drug levies would be set at a “very high” rate, he added that pharma firms would first be given time to bring manufacturing to the U.S.

By Philip Neuffer • July 8, 2025

Novartis gets approval of first malaria medicine for newborns

Coartem Baby, which was cleared by health authorities in Switzerland, will fill an important gap in treatment. Novartis plans to sell it “largely” on a not-for-profit basis.

By Delilah Alvarado • July 8, 2025

[Podcast] Trial Trailblazers: Behind clinical breakthroughs

Explore how innovative clinical trials are transforming treatments for children with rare diseases in this compelling podcast.

By BioPharma Dive's studioID • July 7, 2025

Regeneron bispecific approved for myeloma; Concentra to buy IGM

Lynozyfic is one of two bispecific antibodies Regeneron hopes will lift its oncology business. Meanwhile, IGM is the latest struggling biotech to agree to a buyout deal from Concentra.

By BioPharma Dive staff • July 2, 2025

Biocryst sells Europe business; Peter Marks criticizes new FDA vaccine rules

Biocryst is offloading part of its business for $250 million. Meanwhile, the former FDA leader took issue with a new policy for COVID-19 shots.

By BioPharma Dive staff • June 27, 2025

RFK Jr.-appointed panel recommends flu shots be free of contested preservative

Thimerosal, targeted by activists who claim it’s linked to autism, shouldn't be used in vaccines given in the U.S. this coming flu season, the CDC panel said.

By Jonathan Gardner • Updated June 27, 2025

Incyte replaces CEO Hoppenot with dealmaker Meury

Bill Meury, who shepherded Karuna and Anthos to multibillion-dollar buyouts, will take over Incyte, a successful drug developer now at a crossroads.

By Ned Pagliarulo • June 26, 2025

CDC panel, newly remade by RFK Jr., questions vaccine evidence

New members of the ACIP panel raised questions about the evidence supporting COVID vaccines, and signaled plans to look at other established shots, like those for measles and hepatitis B.

By Delilah Alvarado • June 25, 2025

FDA investigating Elevidys safety; Nektar shares spike on eczema data

The agency said it will evaluate whether regulatory action is needed after investigating the deaths of two patients treated with Sarepta's therapy.

By BioPharma Dive staff • June 24, 2025

Cassidy challenges RFK Jr. with call for delay to CDC vaccine meeting

The GOP senator objected to Secretary Kennedy's recasting of the influential advisory panel, which has sparked criticism from medical groups and Democratic lawmakers.

By Delilah Alvarado • Updated June 24, 2025

New Amgen obesity drug data disappoint Wall Street

Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss effects that weren’t as strong as previously reported.

By Jonathan Gardner • June 24, 2025

Novo abruptly ends obesity drug deal with Hims

The Wegovy maker says the telehealth company didn't stop selling compounded versions of the blockbuster drug after Novo resolved its shortage.

By Jonathan Gardner • Updated June 23, 2025

The rise of GLP-1 drugs: Transforming weight loss treatment

Discover how GLP-1 drugs are reshaping weight loss and treatment horizons.

By Federica Maggiorelli • June 23, 2025

FDA to speed reviews for drugs supporting ‘national interests’

A new pilot program announced by FDA Commissioner Martin Makary would award vouchers that could cut drug reviews to one or two months — but only for products that meet a special criteria.

By Jonathan Gardner • Updated June 18, 2025

Roche, waving off study failures, commits to Phase 3 trials for Parkinson’s drug

The Swiss drugmaker said it was “encouraged” by the signs of effectiveness of the drug, developed by biotech Prothena, showed in two earlier studies that missed their main goals.

By Jonathan Gardner • June 16, 2025

Novo, searching for a spark, plans late-stage trials for amylin drug

The Danish drugmaker, which is grappling with a share decline and competition from Eli Lilly, unveiled planned trials of an obesity medication that works differently than its popular Wegovy. 

By Jonathan Gardner • June 13, 2025

RFK Jr. reveals picks for influential vaccine panel

Days after firing all 17 members of the CDC's Advisory Committee for Immunization Practices, the HHS Secretary named a small new committee that includes multiple vaccine critics.

By Kristin Jensen • June 12, 2025

Pharma’s wins and losses in the budget bill

Key pharma reforms are up in the air as Republicans battle over their mammoth legislation that includes significant healthcare spending cuts.

By Amy Baxter • June 12, 2025

Bristol Myers bolsters radiopharma portfolio with PhiloChem deal

The company is paying $350 million upfront, and potentially over $1.3 billion overall, for a radiopharmaceutical for prostate cancer that works differently than Novartis’ Pluvicto. 

By Kristin Jensen • June 11, 2025

Vaccine makers face fresh uncertainty after firing of CDC panel

The abrupt termination of the 17 panelists guiding the CDC’s vaccine recommendations could yield a new committee more aligned with Robert F. Kennedy Jr.’s skeptical views, analysts warned.

By Delilah Alvarado • June 10, 2025

Merck antibody drug for RSV approved by FDA

Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly became a blockbuster medicine following its approval two years ago.

By Delilah Alvarado • June 9, 2025